Krystal Biotech (4KB) Stock Overview
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4KB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$292.80 |
| 52 Week High | US$334.10 |
| 52 Week Low | US$138.00 |
| Beta | 0.54 |
| 1 Month Change | -1.45% |
| 3 Month Change | -2.40% |
| 1 Year Change | n/a |
| 3 Year Change | 150.26% |
| 5 Year Change | 492.71% |
| Change since IPO | 1,548.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4KB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.2% | 1.6% | -1.1% |
| 1Y | n/a | -0.2% | 3.3% |
Return vs Industry: Insufficient data to determine how 4KB performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 4KB performed against the German Market.
Price Volatility
| 4KB volatility | |
|---|---|
| 4KB Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4KB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4KB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 295 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| 4KB fundamental statistics | |
|---|---|
| Market cap | €8.68b |
| Earnings (TTM) | €210.22m |
| Revenue (TTM) | €383.49m |
Is 4KB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4KB income statement (TTM) | |
|---|---|
| Revenue | US$440.48m |
| Cost of Revenue | US$23.62m |
| Gross Profit | US$416.87m |
| Other Expenses | US$175.40m |
| Earnings | US$241.46m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.16 |
| Gross Margin | 94.64% |
| Net Profit Margin | 54.82% |
| Debt/Equity Ratio | 0% |
How did 4KB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 01:17 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krystal Biotech, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |